ENTA
Enanta Pharmaceuticals Inc
12.00$
+0.4%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 38.4% | 48.5% | 71.1% | 60.2% | 22.4% | 63.2% | 74.0% | 56.0% | – | – | – | 3.5% | 3.0% | – | 7.0% | |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 93.0% | |
| 42.7% | 27.6% | 36.2% | 52.5% | 39.3% | 14.4% | 45.8% | 55.9% | 45.9% | 69.3% | 111.7% | 179.4% | 190.9% | 206.5% | 194.4% | 163.4% | |
| 26.8% | – | 12.7% | 19.3% | 21.0% | 8.4% | 19.2% | 20.2% | 11.3% | 12.8% | 22.3% | 33.5% | 52.8% | 66.8% | 85.5% | 67.3% | |
| 69.5% | 39.6% | 49.0% | 71.8% | 60.2% | 22.8% | 65.1% | 76.1% | 57.3% | 82.1% | 134.0% | 212.9% | 243.7% | 273.2% | 279.9% | 223.6% | |
| 30.5% | 60.4% | 51.0% | 28.2% | 39.8% | 77.2% | 34.9% | 23.9% | 42.7% | 17.9% | -34.0% | -112.9% | -143.7% | -173.2% | -179.9% | -130.7% | |
| 0.0% | 7.5% | 0.0% | 0.1% | 0.0% | 0.0% | 0.1% | 0.0% | 2.3% | 4.3% | 8.4% | 5.5% | 1.8% | 6.5% | 16.2% | 11.8% | |
| 34.0% | 55.7% | 51.3% | 30.0% | 40.4% | 78.0% | 36.9% | 26.2% | 45.1% | 22.2% | -28.6% | -110.8% | -141.8% | -165.4% | -174.2% | -127.9% | |
| -0.7% | 7.5% | – | -0.7% | -31.8% | 28.9% | 12.3% | 9.0% | 10.2% | -0.4% | 0.9% | -29.4% | -0.5% | 3.6% | -2.6% | -2.5% | |
| 34.7% | 55.7% | 51.3% | 30.0% | 72.1% | 49.1% | 24.5% | 17.2% | 34.8% | 22.6% | -29.5% | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% | |
| 36.5% | 64.4% | 51.7% | 28.9% | 40.5% | 77.6% | 36.8% | 26.0% | 44.0% | 19.5% | -31.0% | -109.4% | -138.4% | -155.9% | -154.5% | -108.4% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.